AI Article Synopsis
- The study compares the effectiveness of the BCH-2003 and CCLG-2008 treatment protocols for children with TEL-AML1 fusion gene positive acute lymphoblastic leukemia (ALL).
- Both treatment groups showed similar clinical characteristics, but the BCH-2003 protocol resulted in a lower rate of minimal residual disease (MRD) compared to the CCLG-2008.
- Despite the faster reduction of leukemia load with BCH-2003, the overall outcomes (event-free survival and relapse-free survival) for both protocols were found to be comparable.
Article Abstract
This study was aimed to compare the curative effect of BCH - 2003 protocol and CCLG - 2008 protocol for children with TEL-AML1 fusion gene positive childhood acute lymphoblastic leukemia (ALL) and to investigate the more suitable protocol for this subtype of childhood leukemia. The clinical data for children with TEL-AML1 fusion gene positive ALL admitted from January 2003 to October 2010 in Hematology Center of Beijing Children's Hospital were collected. The common clinical characteristics including prednisone response at day 8, minimal residual disease (MRD) at the end of induction of remission (day 33), event free survival (EFS), relapse free survival (RFS) were compared. The results showed that out of 204 children with TEL-AML1 fusion gene positive ALL, 134 and 70 patients were treated by BCH-2003 protocol and CCLG-2008 protocol respectively. There were no statistical difference in age, white blood cell count in peripheral blood at presentation, prednisone response and CNS involvement. However, there were more boys in CCLG-2008 group (P = 0.025). The negative rate of MRD at day 33 in BCH-2003 group was lower than that in CCLG-2008 group (P = 0.013). After re-stratifying the patients in CCLG-2008 group according to the stratification criteria of BCH-2003 protocol, the negative rate of MRD at day 33 of patients with intermediate risk remained higher in BCH-2003 group than that in CCLG-2008 group (P = 0.014) . However, no significant difference in the patients with standard risk was found. There were also no significant statistical differences in the incidence of severe infection, EFS and RFS, (P = 1.000, P = 0.327,P = 0.251 respectively) during chemotherapy. It is concluded that for children with TEL-AML1 fusion gene positive ALL, the induction of remission of BCH - 2003 protocol can decrease leukemic load more quickly than that of CCLG - 2008 protocol. However, the outcome of the patients treated by the two protocols is similar.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7534/j.issn.1009-2137.2014.02.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Case report: Identification of a novel transcript with -ITD mutation in acute myeloid leukemia progressed from myelodysplastic syndrome.
Front Oncol
December 2024
Department of Hematology, Affiliated Wuxi People's Hospital, Nanjing Medical University, Wuxi, China.
Acute myeloid leukemia (AML), which is most common in adults, is a challenging hematological malignancy. The occurrence and the progression of AML are often accompanied by various gene fusions and/or mutations. Herein, we report the first case of a fusion transcript with a translocation of (1;12)(q25;p13) in AML progressed from myelodysplastic syndrome (MDS) combined with an -ITD (internal tandem duplication) mutation.
View Article and Find Full Text PDFCase report: Therapeutic response to lorlatinib in advanced large-cell neuroendocrine carcinoma of the lung and breast cancer: a heterochronous double malignancy perspective.
Front Pharmacol
December 2024
Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Background: Driver mutations in tyrosine kinases, such as the anaplastic lymphoma kinase (ALK) mutation, are known to play a critical role in the pathogenesis of non-small cell lung cancer (NSCLC) but are rarely observed in large cell neuroendocrine carcinoma (LCNEC). Multiple primary malignancies (MPMs) refer to the occurrence of two or more distinct primary malignancies within the same or different organs and tissues in a single patient, either simultaneously or sequentially.
Case Presentation: We reported a case of advanced LCNEC as a heterochronous double primary malignancy, following a prior breast cancer diagnosis in a 55-year-old woman.
Improvement of silage characteristics of HMC4 and improvement of silage quality of king grass.
Front Microbiol
December 2024
Zhanjiang Experimental Station, Chinese Academy of Tropical Agricultural Sciences, Zhanjiang, China.
The effect of HMC4 produced by protoplast fusion on silage was studied. The silage formula was composed of heterozygote HMC4 (Group C), parent Lactobacillus (Group A) and a combination of two parents (Group B). The fermentation quality and microbial composition of each batch of silage were evaluated.
View Article and Find Full Text PDFThe Genetic and Molecular Drivers of Multiple Myeloma: Current Insights, Clinical Implications, and the Path Forward.
Pharmgenomics Pers Med
December 2024
Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Background: Multiple myeloma (MM) is a hematological malignancy characterized by the clonal proliferation of malignant plasma cells within the bone marrow. The disease's complexity is underpinned by a variety of genetic and molecular abnormalities that drive its progression.
Methods: This review was conducted through a state-of-The-art literature search, primarily utilizing PubMed to gather peer-reviewed articles.
Investigation of the molecular mechanism of quercetin in inhibiting ankylosing spondylitis ossification via the bone morphogenetic protein/smad signaling pathway.
Med Mol Morphol
December 2024
Graduate School, Tianjin Medical University, Tianjin, 300070, China.
Ankylosing spondylitis (AS) is a chronic inflammatory disease involving the spine and bone joints, which is characterized by hyperosteogeny, ossification of ligaments, and ankylosis. Quercetin is a natural polyphenolic compound with various biological activities such as antioxidant, anti-inflammatory, and anti-tumor. It was to explore the effect of quercetin on AS ossification and its molecular mechanism.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!